36 studies found for:    "Cutaneous mastocytosis"
Show Display Options
RSS Create an RSS feed from your search for:
"Cutaneous mastocytosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Efficacy and Safety of TF002 in Cutaneous Mastocytosis
Condition: Cutaneous Mastocytosis
Intervention: Drug: TF 002
2 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions: Smouldering Systemic Mastocytosis;   Indolent Systemic Mastocytosis;   Cutaneous Mastocytosis With Handicap;   Mastocytosis
Interventions: Drug: masitinib (AB1010);   Drug: placebo
3 Completed Natural History of Urticaria Pigmentosa in Children
Condition: Urticaria Pigmentosa
Intervention:
4 Recruiting Study of Factors Regulating Mast Cell Proliferation
Condition: Mastocytosis
Intervention:
5 Completed Cause and Natural Course of Pediatric-Onset Mastocytosis
Condition: Mastocytosis
Intervention:
6 Completed Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
Condition: Patients With Mastocytosis With Handicap and Bearing Mutations Asp-816-Val (D816V)
Intervention: Drug: masitinib
7 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
8 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
9 Completed
Has Results
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: RAD001 (Everolimus)
10 Completed Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Conditions: Nonneoplastic Condition;   Precancerous Condition
Intervention: Drug: thalidomide
11 Terminated Cromoglicate in Mastocytosis
Condition: Mastocytosis
Interventions: Drug: Cromoglicate;   Drug: Placebo
12 Completed Characteristics of Mast Cells in Mastocytosis
Condition: Mastocytosis
Intervention:
13 Recruiting Study of Mast Cell Precursors
Condition: Mastocytosis
Intervention:
14 Completed Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
Condition: Mastocytosis
Intervention: Drug: masitinib (AB1010)
15 Completed Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
Conditions: Mastocytosis;   Anaphylaxis
Intervention:
16 Recruiting The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
17 Terminated
Has Results
Obatoclax for Systemic Mastocytosis
Conditions: Leukemia;   Systemic Mastocytosis
Intervention: Drug: Obatoclax Mesylate
18 Unknown  Imatinib in KIT-negative Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Imatinib Mesylate
19 Completed Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Conditions: Hypereosinophilic Syndrome;   Systemic Mastocytosis;   Chronic Myelomonocytic Leukemia;   Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
20 Recruiting A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years